An executive with over 20 years’ experience in the Pharmaceutical industry, Beverley has held a number of Commercial Finance, Business Development and Business Leadership roles in AstraZeneca. She is the former Vice-President and Head of Operations for Global Medicines Development (GMD) where she supported the Executive Vice-President and Chief Medical Officer and the GMD leadership team to ensure that critical initiatives, and day-to-day operations are in step with the Strategic Business Plan and timelines. GMD is the science unit at AstraZeneca responsible for the late-stage pipeline of potential new medicines. This included the design and delivery of clinical trials around the world to secure regulatory approval, and generating evidence to show the life-changing value of these medicines, ensuring prescribers have the information they need to make the right treatment choice.
Prior to GMD, Beverley was Vice-President, Finance, and Enabling Operations for the Business Development group where she led the financial evaluation and negotiation of a significant number of licensing deals and acquisitions. One of them was the financial evaluation and due diligence for the USD15bn acquisition of MedImmune, a NASDAQ-listed biopharmaceutical company.
Beverley is a Chartered Accountant by training, and has Joint Honours Bachelor of Arts degree in French and Spanish.